How should apixaban be discontinued and resumed around a Mohs surgery, considering the patient’s renal function and the size of the surgical defect?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Apixaban Management for Mohs Surgery

For Mohs surgery, apixaban should be discontinued 24 hours before the procedure (skip 1 dose) if the patient has normal renal function, and resumed 24 hours after surgery once adequate hemostasis is achieved.

Preoperative Management

Mohs surgery is classified as a low bleeding risk procedure based on the nature of the surgery (dermatologic, easily controlled bleeding site) 1. The FDA label explicitly states that apixaban should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where bleeding would be non-critical in location and easily controlled 1.

Discontinuation Protocol Based on Renal Function:

For patients with normal or mild renal impairment (CrCl ≥50 mL/min):

  • Stop apixaban 2 days before surgery (skip 2 doses)
  • This corresponds to 2-3 half-lives, resulting in 3-6% residual anticoagulant effect 2

For patients with moderate renal impairment (CrCl 30-50 mL/min):

  • Stop apixaban 3 days before surgery (skip 4 doses)
  • This allows 4 half-lives to elapse, accounting for prolonged drug clearance 2

The 2022 CHEST guidelines support a pharmacokinetic-based approach, recommending withholding DOACs for 1 full day (30-36 hours) before low-to-moderate bleeding risk procedures 3. Recent research confirms that discontinuation for at least 48 hours results in clinically insignificant anticoagulation levels (94% of patients achieved apixaban concentrations ≤30 ng/mL) 4.

Postoperative Resumption

Resume apixaban 24 hours after surgery once adequate hemostasis is established 2. For low bleeding risk surgery like Mohs, the guideline recommendation is:

  • Standard dose: 5 mg twice daily starting the day after surgery (24 hours postoperative) 2
  • No dose reduction is needed unless the patient is at high risk for thromboembolism 2

The FDA label emphasizes that bridging anticoagulation during the 24-48 hours after stopping apixaban is not generally required 1.

Important Considerations

Surgical Defect Size

While the question mentions surgical defect size, the bleeding risk classification for Mohs surgery remains low regardless of defect size, as the bleeding location is non-critical and easily controlled 1. The same discontinuation protocol applies.

Renal Function Impact

Apixaban has 25% renal clearance 2, making it less dependent on kidney function than dabigatran. However, patients with moderate renal impairment require longer preoperative interruption (3 days vs 2 days) 2.

Common Pitfalls to Avoid:

  • Do not bridge with heparin - this is unnecessary for low-risk procedures and increases bleeding risk 1
  • Do not resume full-dose apixaban too early - wait at least 24 hours for adequate wound hemostasis 2
  • Do not forget to assess renal function - this directly impacts the preoperative interruption interval 2

Delayed Hematoma Risk

Recent case reports document delayed-onset hematomas (>2 weeks postoperatively) in patients continuing apixaban through Mohs surgery 5. This reinforces the importance of proper discontinuation, even for low-risk procedures.

High-Risk Thromboembolism Patients

For patients at high thromboembolism risk (e.g., recent stroke, mechanical valve), consider reduced-dose apixaban 2.5 mg twice daily for the first 2-3 days after surgery before resuming full dose 2. However, this is rarely necessary for routine Mohs procedures given the short interruption period.

References

Related Questions

When should apixaban (Eliquis) be discontinued before bladder surgery?
In a patient with atrial fibrillation taking apixaban (Eliquis), how many days should the medication be discontinued prior to surgical procedures?
Can a patient undergo ureteroscopy and stone removal 24 hours after taking Eliquis (apixaban) for atrial fibrillation?
How long should apixaban be discontinued before a dental procedure involving bone manipulation?
How long should apixaban (Eliquis) be held before orthopedic surgery?
For a patient on apixaban (Eliquis) undergoing excision of basal cell carcinoma, how long should the medication be held before the procedure?
What is a recommended technique for initiating peripheral intravenous access in a patient with excess adipose tissue in the arm?
How can I obtain peripheral IV access in a patient with deep arm veins when ultrasound is unavailable?
In a patient with hemoglobin 11.1 g/dL, serum iron 142 µg/dL, total iron‑binding capacity 400 µg/dL, and transferrin saturation 36%, what is the likely cause of the anemia and what further evaluation is recommended?
Should a 19‑month‑old child with a hemoglobin of 11.1 g/dL and normal iron studies continue iron supplementation?
What is the differential diagnosis for post‑coital vaginal bleeding?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.